Propanc Biopharma, Inc., a development-stage healthcare company, focuses on the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. The company's lead product is PRP, a formulation that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes acting synergistically. Propanc Biopharma, Inc. has a research collaboration with University of Jaén to commence the POP1 joint drug discovery program. The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. Propanc Biopharma, Inc. was founded in 2007 and is based in Camberwell, Australia.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone610-988-6723
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees1
Next Earnings Date9/16/2019 (Estimated)
OptionableNot Optionable
Propanc Biopharma (OTCMKTS:PPCB) Frequently Asked Questions
What is Propanc Biopharma's stock symbol?
Propanc Biopharma trades on the OTCMKTS under the ticker symbol "PPCB."
When is Propanc Biopharma's next earnings date?
Has Propanc Biopharma been receiving favorable news coverage?
Media coverage about PPCB stock has been trending negative this week, according to InfoTrie. InfoTrie rates the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Propanc Biopharma earned a news sentiment score of -2.3 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Propanc Biopharma.
Who are some of Propanc Biopharma's key competitors?
Some companies that are related to Propanc Biopharma include Nuvo Pharmaceuticals (NRIFF), International Stem Cell (ISCO), Auris Medical (EARS), MusclePharm (MSLP), IntelliPharmaCeutics Intl (IPCI), Acura Pharmaceuticals (ACUR), Wellness Center USA (WCUI), Cotinga Pharmaceuticals (COTQF), Praxsyn (PXYN), Innovus Pharmaceuticals (INNV), Uluru (ULUR), Innovus Pharmaceuticals (INNVD), Midatech Pharma (MTP), Parnell Pharmaceuticals (PARNF) and Anthera Pharmaceuticals (ANTH).
What other stocks do shareholders of Propanc Biopharma own?
Who are Propanc Biopharma's key executives?
Propanc Biopharma's management team includes the folowing people:
- Mr. James Nathanielsz, Acting Chairman, CEO, CFO, Sec., Treasurer & Director (Age 45)
- Dr. Julian Norman Kenyon, Chief Scientific Officer & Director (Age 71)
- Prof. Klaus Kutz, Chief Medical Officer & Member of Scientific Advisory Board
How do I buy shares of Propanc Biopharma?
Shares of PPCB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Propanc Biopharma's stock price today?
One share of PPCB stock can currently be purchased for approximately $1.46.
How big of a company is Propanc Biopharma?
What is Propanc Biopharma's official website?
How can I contact Propanc Biopharma?
Propanc Biopharma's mailing address is 302/6 BUTLER STREET VICTORIA, CAMBERWELL C3, 3124. The company can be reached via phone at 610-988-6723 or via email at [email protected]
MarketBeat Community Rating for Propanc Biopharma (OTCMKTS PPCB)
MarketBeat's community ratings are surveys of what our community members think about Propanc Biopharma and other stocks. Vote "Outperform" if you believe PPCB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PPCB will underperform the S&P 500 over the long term. You may vote once every thirty days.
